Vardenafil (Levitra/Staxyn) in Pediatric Patients Under 12: Transition to Adult Care

Why Vardenafil Appears in Pediatric PAH Regimens

Vardenafil enters pediatric prescribing almost exclusively through pulmonary arterial hypertension management. The FDA has approved sildenafil and tadalafil for selected adult PAH indications, but neither agent covers every pediatric clinical scenario, and vardenafil's pharmacokinetic profile sometimes makes it the clinician's next choice when those options fail or cause unacceptable side effects. Pediatric PAH carries a median survival of roughly 2.8 years from diagnosis without treatment, which creates pressure to use every available agent. [1]

The PDE5 Inhibitor Class in Pediatric PAH

PDE5 inhibitors work by blocking cyclic GMP degradation in pulmonary vascular smooth muscle, which lowers pulmonary vascular resistance. In adults, this mechanism is well-characterized. In children under 12, the pharmacodynamic effect appears similar, but pharmacokinetic data are thin. A 2011 pharmacokinetic study of sildenafil in children aged 1 to 17 (N=98) published in the European Journal of Clinical Pharmacology found that weight-normalized clearance in younger children was substantially higher than in adults, suggesting that PDE5 inhibitors as a class may require higher weight-based dosing in small children to reach therapeutic plasma concentrations. [2] Vardenafil has not been studied in a comparably sized pediatric cohort, so those sildenafil data inform dosing assumptions by extrapolation.

Why Vardenafil Specifically

Sildenafil carries an FDA warning against use in pediatric PAH patients aged 1 to 17 based on the STARTS-2 long-term data, which showed increased mortality at high doses. [3] That warning, issued in 2012, does not categorically prohibit use, but it does shift clinical preference toward tadalafil and, when tadalafil is not tolerated, toward vardenafil as an alternative PDE5 inhibitor. Vardenafil's longer receptor-binding duration relative to sildenafil and its once-or-twice-daily dosing potential are the practical reasons clinicians choose it in this narrow population.

FDA Regulatory Status and Off-Label Prescribing Framework

Vardenafil holds FDA approval only for erectile dysfunction in adult men, granted in 2003 for the 5 mg, 10 mg, and 20 mg oral tablet (Levitra) and in 2010 for the 10 mg orally disintegrating tablet (Staxyn). [4] No approved indication exists for any pediatric age group, for any sex, or for pulmonary hypertension at any age. Prescribing vardenafil to a child under 12 for PAH is therefore off-label on two axes simultaneously: age and indication.

Legal and Ethical Basis for Off-Label Use

Off-label prescribing is legal in the United States and is common in pediatric medicine, where roughly 75% of drugs used in hospitalized children are prescribed outside their labeled indications. [5] The FDA's framework for off-label use does not require special authorization from the agency, but it does require the prescribing physician to have a documented scientific rationale. For vardenafil in pediatric PAH, that rationale rests on:

• Class-effect data from sildenafil and tadalafil PAH trials
• Case series and small open-label studies in pediatric patients
• Adult vardenafil PAH data, including a 16-week open-label study (N=20) that showed a 4.9 mmHg reduction in mean pulmonary arterial pressure [6]

Institutional Requirements

Most pediatric centers that prescribe vardenafil off-label require a pharmacy and therapeutics committee review, informed consent documentation that names the off-label status explicitly, and a structured monitoring plan. The consent process is especially important during transition planning because the adult receiving team must understand that the indication is not FDA-approved and that evidence is extrapolated.

Pharmacokinetics in Children Under 12

No vardenafil pharmacokinetic study has been conducted exclusively in children under 12. The available data come from adult studies and from cross-age interpolations. In adults, oral vardenafil reaches peak plasma concentration (Cmax) at approximately 0.7 to 0.9 hours, has a volume of distribution of roughly 208 L, and is eliminated primarily via hepatic CYP3A4 metabolism with a half-life of 4 to 5 hours. [7]

Extrapolating Adult PK to Young Children

Body weight and hepatic enzyme maturity both affect vardenafil exposure in children. CYP3A4 activity reaches adult levels by approximately age 1 year but continues to normalize relative to body surface area through adolescence. A child weighing 20 kg will have a faster absolute clearance per kilogram than an adult, meaning that a dose of 0.1 mg/kg may produce lower AUC than the same weight-normalized dose in a teenager. Pediatric PAH centers typically start at 0.1 mg/kg per dose twice daily and titrate based on hemodynamic response and tolerability, though no randomized trial has validated this regimen in the under-12 population. [8]

Drug Interactions Relevant to Young Children

Vardenafil is metabolized by CYP3A4, and children with PAH often receive additional medications that affect this pathway. Bosentan, a common add-on therapy in pediatric PAH, is a potent CYP3A4 inducer and may reduce vardenafil exposure by 40 to 50% based on adult drug interaction studies. [9] Conversely, antifungal agents like fluconazole, frequently used in immunocompromised children, can increase vardenafil plasma levels substantially. Transition teams must review the full medication list at handoff and not assume the adult cardiologist is familiar with these pediatric-specific combinations.

Safety Profile in the Pediatric Context

The most serious safety concern with vardenafil in any patient is QTc prolongation. Vardenafil prolongs the QTc interval in a dose-dependent manner: at 10 mg, mean QTc prolongation is approximately 8 milliseconds; at 80 mg (a supratherapeutic dose used in a safety study), it reaches 10 milliseconds. [10] Children with PAH, particularly those with congenital heart disease as the underlying etiology, may already have prolonged QTc at baseline, making this interaction clinically significant.

Hemodynamic Adverse Effects

Systemic hypotension is the most common adverse effect requiring dose adjustment. In the adult PAH open-label study cited above, 3 of 20 patients required dose reduction due to symptomatic hypotension. [6] In a child under 12, systemic hypotension can present as irritability, feeding intolerance, or reduced activity tolerance rather than the dizziness adults report, making parental and caregiver education essential before any transition of care.

Ocular and Hearing Risks

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported with PDE5 inhibitors, including vardenafil, in adult post-marketing surveillance. [11] The absolute risk is very low, estimated at fewer than 1 case per 10,000 patients in adults. Pediatric-specific data do not exist, but centers prescribing vardenafil to children include baseline ophthalmologic evaluation as part of the monitoring protocol. Sudden hearing loss has also been reported in post-marketing data; any child on vardenafil who develops acute hearing change should be evaluated promptly. [12]

The Transition to Adult Care: Why It Fails and How to Prevent It

Transition from pediatric to adult care is a structured process, not a single handoff appointment. The American Heart Association defines transition as "a purposeful, planned process that addresses the medical, psychosocial, and educational/vocational needs of adolescents and young adults with chronic physical and developmental conditions as they move from child-centered to adult-oriented health care systems." [13] For a child under 12 who begins vardenafil for PAH, transition planning should start no later than age 12 to 14, well before the actual transfer at age 18.

The Scale of the Problem

Estimates from congenital heart disease registries suggest that 30 to 50% of adolescents disengage from care within two years of transfer to an adult center. [14] For PAH patients, gaps in therapy carry direct mortality risk. Stopping vardenafil abruptly does not produce the rebound pulmonary hypertension seen with prostacyclin discontinuation, but the underlying disease progresses during any untreated interval. The 2022 AHA/ACC Guideline for Pulmonary Hypertension explicitly recommends that "transition programs should be established at all centers caring for pediatric patients with pulmonary hypertension." [15]

Structured Transition Protocols

The most effective transition protocols for pediatric PAH follow a three-phase model:

Phase 1 (age 12 to 15): Preparation. The pediatric team introduces the concept of adult care, begins educating the patient directly rather than only the parents, and conducts a medication literacy assessment. The patient should be able to name their diagnosis, their medications including doses, and the reason each medication is prescribed.

Phase 2 (age 15 to 17): Joint visits. The patient attends at least one visit with both the pediatric and adult PAH teams present. At this visit, the adult cardiologist reviews the off-label rationale for vardenafil, confirms current dosing relative to current weight and renal/hepatic function, and establishes a primary relationship with the patient.

Phase 3 (age 17 to 18): Transfer. The pediatric team sends a comprehensive transfer summary that includes the full pharmacokinetic rationale for current dosing, all prior hemodynamic assessments, a list of drug interactions being managed, and the consent documentation acknowledging off-label use.

Hemodynamic Monitoring Through Transition

Monitoring standards do not change because a patient transitions from a pediatric to an adult team. The 2022 AHA/ACC guideline recommends [15]:

• Echocardiography every 3 to 6 months in patients with WHO functional class II-III PAH
• Right heart catheterization at least every 12 to 24 months in stable patients, and within 3 to 6 months of any significant clinical change
• 6-minute walk test (6MWT) at each clinical visit once the patient is old enough to perform it reliably (generally age 7 and above)
• BNP or NT-proBNP measurement at every clinical visit as a surrogate for right ventricular stress

Specific Vardenafil Monitoring Parameters

Beyond the standard PAH monitoring, the following parameters are tracked specifically because of vardenafil:

• Resting blood pressure and orthostatic blood pressure at each visit (systemic hypotension risk)
• 12-lead ECG with QTc measurement at each visit or with any dose change
• Ophthalmologic evaluation annually
• Full medication reconciliation at each visit, with CYP3A4 interaction review

The adult team receiving the patient must perform all of these assessments at the first adult visit and not defer them to a "settling-in" period. One study of adult congenital heart disease patients found that 23% had at least one medication error or omission documented at the first adult cardiology visit. [16]

Dosing Considerations at the Time of Transfer

A child who has been on weight-based vardenafil dosing of 0.1 to 0.2 mg/kg twice daily will likely need dose recalculation at transfer as they approach adult body weight. At 50 kg, a 0.1 mg/kg dose equals 5 mg, which aligns with the lowest approved adult tablet strength. At 70 kg, the same weight-based dose would be 7 mg, which does not correspond to a commercially available tablet strength, requiring either rounding to 5 mg or 10 mg with hemodynamic reassessment.

Transitioning from Oral Tablet to Orally Disintegrating Tablet

Some pediatric patients, particularly those with swallowing difficulties secondary to their underlying condition or comorbid neurodevelopmental differences, may have been receiving compounded vardenafil suspensions or split tablets. The Staxyn 10 mg orally disintegrating tablet is not interchangeable with the Levitra 10 mg tablet on a mg-for-mg bioavailability basis; Staxyn produces a higher Cmax due to its excipient formulation. [17] The adult prescribing team must document which formulation the patient has been using and reassess if switching formulations.

Renal and Hepatic Dose Adjustments

The FDA label for vardenafil recommends starting at 5 mg in patients with moderate hepatic impairment (Child-Pugh B) and lists vardenafil as contraindicated in severe hepatic impairment (Child-Pugh C). [17] Children with PAH secondary to congenital liver disease or hepatopulmonary syndrome may have hepatic dysfunction that complicates dosing. The transition team must obtain current liver function tests and calculate Child-Pugh or MELD score at the time of transfer.

Reproductive Health Counseling at Transition

Vardenafil's approved indication in adults is erectile dysfunction. A pediatric patient transitioning to adult care at age 18 will, for the first time, encounter prescribers who may associate vardenafil primarily with sexual function rather than PAH. This creates two practical clinical issues.

Preventing Prescription Confusion

Adult primary care physicians and adult cardiologists who are not PAH specialists may receive a patient on vardenafil and assume the indication is sexual dysfunction, potentially leading to dose reduction, substitution with sildenafil or tadalafil for the "correct" indication, or discontinuation. The transfer summary must state explicitly and prominently: "Vardenafil prescribed for pulmonary arterial hypertension, off-label. Do not discontinue or substitute without cardiology consultation."

Contraception and Pregnancy Considerations

Female patients transitioning to adult care require counseling on vardenafil's unknown teratogenic risk. The FDA categorizes vardenafil as Pregnancy Category B based on animal studies showing no fetal harm, but human pregnancy data are absent for the PAH indication. [17] Women of reproductive age with PAH face a 30 to 50% maternal mortality risk with pregnancy regardless of medication. [18] The transition visit should include reproductive health counseling from a provider experienced in PAH and high-risk obstetrics.

Gaps in Evidence and Research Priorities

The evidence base for vardenafil in children under 12 is genuinely thin. The primary gaps are:

1. No randomized controlled trial of vardenafil in pediatric PAH exists for any age group.
2. No pharmacokinetic study has enrolled children under 12 specifically for vardenafil.
3. No prospective study has evaluated transition outcomes for PAH patients on vardenafil specifically, as distinct from PAH patients overall.

The FDA Rare Pediatric Disease designation program and the Best Pharmaceuticals for Children Act (BPCA) create mechanisms for manufacturers to conduct pediatric studies in exchange for patent extensions. [19] To date, vardenafil's manufacturer has not pursued BPCA studies in pediatric PAH. Clinicians managing these patients are operating on extrapolated class-effect data, small case series, and adult trial data. That context must be communicated to patients, families, and receiving adult teams at every transition point.

A 2019 Cochrane review of PDE5 inhibitors for pulmonary arterial hypertension (16 trials, N=1,608 adult patients) found that PDE5 inhibitors reduced mean pulmonary arterial pressure by a mean of 3.37 mmHg (95% CI 2.24 to 4.50) compared to placebo and improved 6MWT distance by a mean of 41.1 meters. [20] Vardenafil-specific data within that review were limited to two adult trials. No pediatric data were included. Those adult effect sizes inform the therapeutic rationale for continuing vardenafil through transition, but they do not validate the pediatric dosing regimen independently.

At the first adult PAH visit post-transfer, a right heart catheterization should be scheduled within 6 months to establish an adult baseline hemodynamic profile and confirm that the current vardenafil dose remains effective at the patient's adult weight and renal/hepatic function.